Urolithin A has moved from niche scientific interest to commercially available supplement in a short span of years, and ProHealth Longevity is one of the more prominent companies selling it. The compound’s appeal centers on a specific cellular mechanism (mitophagy, the clearance of damaged mitochondria) that researchers believe may support healthy aging at a fundamental level. But supplement marketing often outruns the evidence, and urolithin A is no exception to that risk.
This review examines what the published science actually supports about urolithin A: where it comes from, how it is proposed to work, what the human clinical data shows, and what to look for when evaluating any commercial product in this category. We cite only research from peer-reviewed literature and are explicit about where findings are preliminary, limited to animal models, or have not yet been replicated in human trials.
Key Takeaways
- Urolithin A is a gut metabolite from ellagitannin-rich foods; direct supplements bypass unreliable individual conversion, and in a trial of 100 US adults 33% made no urolithin A from pomegranate juice and another 27% made little [11][12][1].
- Its core proposed mechanism is mitophagy, stimulating clearance of damaged mitochondria, which declines with age and is associated with declining cellular energy metabolism.
- An early 4-week safety and biomarker trial showed molecular signals consistent with improved mitochondrial health at 500 and 1,000 mg/day; later 4-month trials in middle-aged and older adults have measured function and missed their primary endpoints [2][13][14].
- Formulation may matter: liposomal and encapsulated forms have shown improved stability and bioaccessibility in laboratory and animal models, but no human trial has compared them with plain urolithin A [3][15][16].
- Preliminary animal studies suggest wider potential effects in cognition, liver function, and cardioprotection, but none of these have been established in human trials and should not drive purchasing decisions.
What Is Urolithin A and Where Does It Come From?
Urolithin A is not a nutrient you consume directly: it is a metabolite produced by your gut microbiome when intestinal bacteria break down ellagitannins and ellagic acid from plant foods. Pomegranates, walnuts, and certain berries are among the richest dietary sources of these precursor compounds [4]. Once absorbed, urolithin A circulates in the bloodstream and has been detected in various tissues, where it appears to exert biological effects.
A significant practical complication is that conversion varies considerably between individuals, and how many people are nonproducers depends on the study: in a trial of 100 US adults, 33% made no urolithin A from pomegranate juice and another 27% made little, and reviews report 5 to 25% of people with no detectable urolithins; the required bacterial species are not uniformly present [11][12][1]. Two people eating identical pomegranate-rich diets may have very different plasma urolithin A concentrations. This variability is the central reason direct supplementation has attracted commercial interest: it bypasses the unpredictable conversion step entirely.
For context on precursor foods: strawberries contain ellagic acid precursors and contribute to postprandial antioxidant activity [5], and black raspberries have been studied for their ellagic acid content in other health contexts [6]. Neither food reliably delivers therapeutically relevant urolithin A concentrations for most people, reinforcing the case for a supplement if someone specifically wants systemic urolithin A exposure.
The Mitophagy Mechanism: What Researchers Believe Is Happening
The biological story behind urolithin A centers on mitophagy: the quality-control process by which cells identify dysfunctional mitochondria, tag them, and clear them through the autophagy pathway. Mitochondria are the energy-producing organelles inside virtually every cell; as they accumulate damage over time, they can become less efficient and generate excess oxidative stress. Mitophagy is the mechanism that prevents this accumulation [1].
Research note: In the 4-month trial in middle-aged adults, 102 adverse events were reported by 45 participants: 42 (17 participants) on placebo, 24 (13 participants) on 500 mg and 36 (15 participants) on 1,000 mg. The authors judged urolithin A safe and well tolerated at both doses [13].
With age, mitophagy efficiency tends to decline, allowing defective mitochondria to persist and build up: a process associated with declining cellular energy metabolism and increased inflammatory signaling. Urolithin A has been shown in cell culture and animal models to activate key mitophagy regulators, including the PINK1-Parkin pathway, promoting the clearance of damaged mitochondria and supporting renewal of the mitochondrial pool [2]. This is mechanistically distinct from simply providing antioxidant protection; it acts on a cellular maintenance pathway.
It is important to understand that much of the mechanistic research has been conducted in cell lines and rodent models. While these findings point toward a plausible and interesting biological effect, they do not by themselves confirm that the same processes operate at clinically meaningful scale in healthy adult humans. That question requires well-designed human trials.
Human Clinical Evidence: The Landmark 2019 Trial
The most cited human study on urolithin A is a randomized controlled trial published in Nature Metabolism, which enrolled healthy older adults and tested single and repeated doses over 4 weeks, with plasma changes reported at 500 and 1,000 mg [2]. The primary finding was that urolithin A was safe and well-tolerated at all doses tested, with no significant adverse events attributable to the compound.
Beyond safety, the researchers observed a molecular signature consistent with improved mitochondrial and cellular health. Participants taking urolithin A showed changes in plasma acylcarnitine profiles, biomarkers reflecting mitochondrial fatty acid oxidation, and upregulation of mitophagy-related gene expression in skeletal muscle biopsies [2]. The study authors characterized these as biomarker changes rather than direct clinical outcomes such as increased muscle strength, improved physical performance, or reduced disease risk.
This distinction is critical for consumers evaluating supplement claims. Biomarker changes demonstrate that urolithin A is biologically active in humans and producing molecular signals consistent with its proposed mechanism: this is meaningful and distinguishes it from many compounds that simply show nothing in humans. However, biomarker changes do not by themselves confirm functional or health benefits. Longer trials with functional endpoints now exist: two 4-month trials (88 middle-aged and 66 older adults) missed their primary endpoints, with some secondary measures favouring urolithin A [13][14].
Later trials did measure function. In 88 middle-aged adults over 4 months, the primary endpoint (peak cycling power) did not change significantly, and in 66 older adults the primary endpoints (walking distance and muscle ATP production) did not improve versus placebo. Both trials were funded by Amazentis, the company behind Mitopure [13][14].
Bioavailability: Why Formulation Matters
Urolithin A is a lipophilic molecule, it dissolves in fat rather than water, which creates absorption challenges when delivered orally. The proportion of an ingested dose that reaches systemic circulation in active form varies considerably depending on the formulation, and this matters practically because a lower-bioavailability product at the same labeled dose delivers less active compound to tissues [1].
Researchers have explored delivery improvements with some interesting results. A comparative study found that liposomal encapsulation significantly improved the stability, bioaccessibility, and bioavailability of urolithin A compared to unencapsulated free form [3]. A separate investigation into gum arabic-coated urolithin A nanoparticles also demonstrated improved bioavailability and enhanced effects in a preclinical liver disease model [7]. These are early-stage formulation studies and have not all been replicated in human pharmacokinetic trials, but they only suggest that how urolithin A is packaged may influence how well it works in people [16].
When evaluating ProHealth Longevity’s urolithin A or any competitor product, it is worth identifying the specific form (free acid, liposomal, or nanoparticle-based), whether third-party analytical testing confirms actual content and purity, and whether the dose falls within the range studied in published human research: 250 mg to 1000 mg per day in the available trial [2].
Emerging Research Areas: Cognition, Liver Health, and Cardioprotection
Outside of the muscle-and-mitochondria framework, urolithin A is being investigated in a range of other biological contexts. A 2025 animal study found that urolithin A alleviated schizophrenic-like behaviors and cognitive impairment in rats, with proposed mechanisms involving reduced neuroinflammation, improved neurogenesis, and enhanced synaptic plasticity [8]. These are intriguing early-stage findings; rodent cognition studies have a poor track record of direct translation to humans, but they point to biological activity in neural tissue worth following.
In a study using aging laying hens, dietary urolithin A improved hepatic antioxidant function and was associated with activation of the Nrf2 signaling pathway: a master regulator of cellular antioxidant defense [9]. Separately, urolithin A-laden nanoparticles were found to reduce cisplatin-induced cardiac damage in mice by inhibiting inflammation-driven lymphangiogenesis [10]. Both are animal models, and neither finding has been evaluated in human cardiovascular or liver trials.
The breadth of this early research reflects genuine scientific interest in urolithin A’s potential pleiotropic effects: the idea that activating mitophagy and Nrf2 pathways could benefit multiple organ systems simultaneously. Consumers should treat these findings as hypothesis-generating, not as established benefits to expect from a supplement.
What to Look For in a Urolithin A Supplement
ProHealth Longevity positions itself as a research-oriented longevity brand. Regardless of brand, the meaningful criteria for evaluating a urolithin A supplement are consistent: dose alignment with studied amounts (250 to 1000 mg/day), form and bioavailability considerations, third-party testing for purity and label accuracy, and marketing claims that stay within what human evidence supports. The 2019 Nature Metabolism trial established safety and biomarker activity at these doses [2]; claims extending to disease prevention or guaranteed functional outcomes go beyond the published record.
Urolithin A supplements are regulated as dietary supplements, not drugs, meaning manufacturers do not need to demonstrate efficacy before selling. Price variation in this category is significant, and premium pricing alone is not a reliable indicator of superior bioavailability or purity. Independent certification (NSF, USP, or Informed Sport) provides meaningful quality assurance that bare minimum regulatory compliance does not.
🛒 Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day: The clinically studied form (Amazentis); used in the human trials. - Pure Encapsulations Renual
caplique capsules, 250 mg Mitopure Urolithin A/serving (with resveratrol + CoQ10): adds resveratrol and CoQ10, a combination the published urolithin A trials did not test. - ProHealth Longevity Urolithin A
capsules, 500 mg: Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg: Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
The human evidence for urolithin A is early-stage: the longest published trials ran about 4 months and missed their primary endpoints, with mixed results on functional measures [13][14], and long-term safety data is not yet available. This article is informational only and does not constitute medical advice; individuals with health conditions, those taking prescription medications, and anyone who is pregnant or nursing should consult a qualified healthcare provider before using any urolithin A supplement.
Frequently Asked Questions
What is urolithin A and why can't I just get it from food?
Urolithin A is produced by gut bacteria from plant compounds called ellagitannins, found in pomegranates, walnuts, and certain berries [4]. The problem is that conversion varies considerably between individuals and many people are nonproducers or poor producers (in a trial of 100 US adults, 33% made no urolithin A from pomegranate juice and another 27% made little, and reviews report 5 to 25% of people with no detectable urolithins), making dietary intake unreliable for some individuals [1][11][12]. Supplements provide the compound directly without depending on individual microbiome composition.
What does the human research actually show?
The primary human study found that urolithin A was safe at doses up to 1000 mg/day over 28 days and produced molecular biomarker changes consistent with improved mitochondrial health, including shifts in acylcarnitine profiles and increased mitophagy-related gene expression in muscle tissue [2]. These are biomarker findings, not clinical outcomes; longer trials are needed to determine whether these changes translate to measurable functional benefits.
Is urolithin A safe to take?
In the published human trial, urolithin A was well-tolerated at all doses tested (250 mg, 500 mg, and 1000 mg daily) with no significant adverse effects attributed to the supplement [2]. Long-term safety data in humans beyond 28 days is not yet available in the published literature. Anyone with a health condition or taking prescription medications should consult a healthcare provider before starting any new supplement.
Does the form or formulation of urolithin A matter?
Yes: urolithin A is lipophilic and absorption can vary between formulations. Research has shown that liposomal encapsulation improves stability, bioaccessibility, and bioavailability compared to unencapsulated forms [3], suggesting that how the compound is packaged can affect how much reaches the bloodstream and tissues.
Are there benefits beyond muscle and mitochondria?
Preliminary animal research points to potential effects on neuroinflammation and cognition [8], hepatic antioxidant function via Nrf2 activation [9], and protection against inflammatory cardiac damage [10]. All of these findings come from animal models; none have been confirmed in human clinical trials and should be treated as early-stage signals rather than established benefits.
How does ProHealth Longevity's product compare to other urolithin A supplements?
Without independent third-party pharmacokinetic data comparing specific brands, meaningful head-to-head comparison is difficult. The most useful evaluation criteria for any product, including ProHealth’s, are dose alignment with studied amounts (250 to 1000 mg/day from the published trial [2]), formulation transparency, third-party purity testing, and whether marketing claims stay within what human evidence supports rather than extrapolating from animal studies.
References
- Yuan H et al. Urolithin A From Gut Metabolite to Therapeutic Agent: Bioavailability, Mechanisms, and Translational Insights. Journal of food science (2026). PMID 41866331
- Andreux PA et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature metabolism (2019). PMID 32694802
- Hu Y et al. Liposomes encapsulation by pH driven improves the stability, bioaccessibility and bioavailability of urolithin A: A comparative study. International journal of biological macromolecules (2023). PMID 37865359
- Zhang M et al. Ellagic acid and intestinal microflora metabolite urolithin A: A review on its sources, metabolic distribution, health benefits, and biotransformation. Critical reviews in food science and nutrition (2023). PMID 35142569
- Prymont-Przyminska A et al. Addition of strawberries to the usual diet increases postprandial but not fasting non-urate plasma antioxidant activity in healthy subjects. Journal of clinical biochemistry and nutrition (2016). PMID 27895386
- Eskra JN et al. Effects of Black Raspberries and Their Ellagic Acid and Anthocyanin Constituents on Taxane Chemotherapy of Castration-Resistant Prostate Cancer Cells. Scientific reports (2019). PMID 30867440
- Zhang L et al. Gum arabic-coated urolithin A liposome nanoparticles: Fabrication, characterization, bioavailability and improved alleviation on NAFLD activity in vivo. Carbohydrate polymers (2026). PMID 42097775
- Huang Z et al. Urolithin A alleviates schizophrenic-like behaviors and cognitive impairment in rats through modulation of neuroinflammation, neurogenesis, and synaptic plasticity. Scientific reports (2025). PMID 40140679
- Wu L et al. Dietary urolithin a improves hepatic antioxidant function and laying performance in aging hens via Nrf2 signaling pathway activation. Poultry science (2026). PMID 41564535
- Wahab AT et al. Urolithin A-laden functional nanoparticles alleviate cisplatin-induced cardiotoxicity in mice by inhibiting inflammation-induced lymphangiogenesis. Free radical biology & medicine (2025). PMID 40516794
- Singh A et al. Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population. European journal of clinical nutrition (2022). PMID 34117375
- Francisco Abraham Tomás-Barberán et al. Ellagic Acid Metabolism by Human Gut Microbiota: Consistent Observation of Three Urolithin Phenotypes in Intervention Trials, Independent of Food Source, Age, and Health Status. Journal of Agricultural and Food Chemistry (2014). PMID 24976365
- Singh A et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell reports. Medicine (2022). PMID 35584623
- Liu S et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA network open (2022). PMID 35050355
- Timeline (Amazentis) How to select the most effective urolithin A supplement. Timeline (Amazentis) (2026). source
- García-Villalba R et al. Urolithins: a Comprehensive Update on their Metabolism, Bioactivity, and Associated Gut Microbiota. Molecular nutrition & food research (2022). PMID 35118817
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.